¡Ya estamos en ! Descubre más
11.80 USD
-0.88
6.94%
Al cierre Actualizado 16 oct, 4:00 p.m. EDT
Antes de la apertura del mercado
Después del cierre del mercado
11.80
0.00
0%
1 día
-6.94%
5 días
-7.16%
1 mes
1.11%
3 meses
91.56%
6 meses
208.09%
En lo que va del año
244.02%
1 año
102.05%
5 años
-22.77%
10 años
-79.97%
 

Acerca de: AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Empleados: 562

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 34.8%
Neutral 60.9%
Negativo 4.3%
Neutral
Business Wire
hace 8 días
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
Neutral
Business Wire
hace 15 días
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Positivo
Zacks Investment Research
hace 24 días
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
Neutral
Business Wire
el mes pasado
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
Neutral
Business Wire
el mes pasado
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
Positivo
Benzinga
el mes pasado
What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
What'sGoing On With AbCellera Biologics Stock On Tuesday?
Positivo
Seeking Alpha
hace 2 meses
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
Neutral
Business Wire
hace 2 meses
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
Positivo
Benzinga
hace 2 meses
What's Going on With AbCellera Biologics Stock On Wednesday?
AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at alleviating menopausal hot flashes.
What's Going on With AbCellera Biologics Stock On Wednesday?
Neutral
Business Wire
hace 2 meses
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Gráficos de precios implementados con Lightweight Charts™